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Abstract
Polyclonal antibodies were raised in rabbits against a 14-amino acid portion of the gibbon ape leukemia virus human
membrane receptor Glvr-1. This epitope also contained seven amino acids common to the receptor for the amphotropic
murine retrovirus Ram-1. Antibody specificity and molecular size of Glvr-1rRam-1-related proteins were assayed by
Western blot. Using a standard Laemmli buffer system, under reducing conditions, a single band of approximately 85 kDa
 .  .designated p85 was immunodetected in membranes prepared from opossum kidney OK cells and in brain membranes
from rat, rabbit and hamster. In mouse brain, p85 as well as a protein of 70–72 kDa were immunodetected. This protein was
also present in several other mouse tissues. Limited proteolysis of p85 and the 70–72 kDa-protein from mouse yielded
similar peptide fragments, suggesting that both proteins are related. Fragments of the same molecular masses were also
 .detected in OK cell membranes following proteolysis, showing that p85 in both models mouse brain and OK cell share a
similar sequence. p85 is not N-glycosylated since an assay using endoglycosidase FrN-glycosidase F did not alter the
electrophoretic mobility of p85. We also observed that regulation of phosphate transport by incubating OK cells without any
phosphate or by PTH treatment occurs without any changes in the amount of p85. In conclusion, these data demonstrate for
the first time a Western blot detection of a type III phosphate transporter using polyclonal antibodies. They also suggest
that, conversely to type I and type II phosphate transporters which are localized in the kidney, this third type of transporter
is ubiquitous and probably absorbs the readily available phosphate from interstitial fluid for normal cellular functions in
many species and tissues, serving as a housekeeping NaqrP cotransport system. This is also the first report showing thati
p85 is not regulated in the same manner as type II phosphate transporters. q 1998 Elsevier Science B.V.
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1. Introduction
 .Inorganic phosphate P is essential for cellulari
metabolism, signal transduction, regulation of protein
enzymatic activities, nucleic acid and lipid synthesis.
Regulation of phosphate homeostasis depends primar-
ily on renal proximal tubular phosphate reabsorption
w x1 . About 80% of P in glomerular filtrate is reab-i
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sorbed within the proximal tubule, which is the pri-
mary site of physiological regulation of phosphate
w xreabsorption 2 . Although the cellular mechanisms
underlying phosphate reabsorption are complex and
regulated by many factors, the main site of renal Pi
 .reabsorption is the brush-border membrane BBM of
the proximal tubule, involving predominantly a spe-
w xcific sodiumrphosphate cotransport system 3 . A
family of sodium-dependent phosphate transporters
was found by expression cloning in Xenopus laevis
oocytes: type I and type II Na–P cotransport systemsi
 .i.e. NaP -1 for type I and NaP -2,3,4,5,6 for type IIi i
w x4–8 .
In addition to these two classical, well character-
ized types of transporters, a third type was found. It
includes cell-surface virus receptors that mediate in-
 .fections of gibbon ape leukemia viruses GALV and
of mouse amphotropic retrovirus for gibbon ape
leukemia virus, designated Glvr-1 and Ram-1, respec-
tively. These membrane proteins have been cloned,
sequenced and expressed in Xenopus laevis oocytes
and in mammalian cells, and were found to act as
w xphosphate carriers 9–11 . In addition to the broad
tissue distribution of GVLR-1 and Ram-1 including
bone marrow, thymus, brain, kidney, lung, liver and
w xheart from rat 10 , Glvr-1 mRNA is also present in a
w xwide variety of animal species 12 . Therefore, this
ubiquitous third type of phosphate cotransporter could
provide a major pathway for phosphate uptake into
many mammalian cells. It has been suggested that
Glvr-1 and Ram-1 may act as constitutive
sodiumrphosphate cotransporters present in most cell
types to absorb the readily available phosphate from
w xsurrounding fluids for normal cellular functions 10 .
These three types of transporters share little amino
w xacid sequence homology with each other 10 and
probably have different modes of regulation. For
example, type I and II are mainly found in kidney
cortex while the type III phosphate transporters are
present in various tissues. Furthermore, it has been
clearly shown that type II is upregulated following
w xdepletion of extracellular phosphate 13 . Although a
three to five-fold overexpression of Glvr-1 and Ram-1
mRNAs in rat 208F fibroblasts following P depriva-i
w xtion 10 has been reported, overexpression of the
proteins following low-phosphate diet has never been
presented. A recent report has shown the presence of
Glvr-1 mRNA in osteoblast-like cells, and has sug-
gested a key role for this transporter in phosphate
w xhandling by osteogenic cells 14 .
 .Opossum kidney OK cells, a continuous renal
tubular epithelial cell line, are useful experimental
model to investigate the cellular mechanisms in-
volved in the regulation of phosphate reabsorption
 .e.g. adaptation to phosphate restriction in isolation
w xfrom the complex systemic factors 3,15 . In the
current report, we used biochemical and immuno-
chemical approaches to detect and characterize type
III phosphate transporters in OK cells and brain
membranes from various species.
2. Materials and methods
2.1. Immunization and antibody purification
The peptide GDSGDKPLRRNNSY, corresponding
to a portion of Glvr-1 ranging from amino acid
408–421, was synthesized using MAPS chemistry
and was obtained from Service de Sequence de Pep-´
tides de l’Est du Quebec Centre Hospitalier de´
.l’Universite Laval, Que. at a purity )85%. Seven´
of these amino acids also correspond to a portion of
Ram-1, the receptor for amphotropic murine retro-
virus. On day 0, three rabbits were injected subcuta-
neously at two sites on the back and intramuscularly
at two sites on the rear hind limbs with a total of
400 mg of the Glvr-1 peptide mixed with Freund’s
 .complete adjuvant Pierce, Rockford, IL in a 1:1
volume ratio, i.e. 0.5 ml adjuvant q 0.5 ml of a
solution containing 400 mg peptide. Booster injec-
tions with the same amount of antigen were adminis-
tered on day 34 using Freund’s incomplete adjuvant.
 .The final injection day 50 consisted of 400 mg of
peptide adsorbed to aluminum hydroxide Imject
.Alum, Pierce administered intraperitoneally at two
sites in the lower abdomen. The rabbits were bled 18
days after the final injection. The blood was allowed
to coagulate at room temperature for 1 h and stored
overnight at 48C to allow the clot to retract. The
serum was collected after removal of blood cells by
centrifugation at 10 000=g for 10 min. It was ad-
justed to pH 8.6 with TrisrHCl and, to collect the
IgG, passed through a 22-ml protein A Sepharose 4
 .Fast Flow column Pharmacia, Dorval, Que. equili-
brated with 50 mM TrisrHCl, pH 8.6 using a Fast
Protein Liquid Chromatography apparatus FPLC,
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.Pharmacia, Dorval, Que. . The column was washed
extensively with the same buffer and IgGs were
eluted with 0.2 M glycine, pH 2.2. The fractions
 .4 ml were collected in 0.6 ml of 1 M TrisrHCl, pH
9. The antibodies were further purified by affinity
chromatography on a peptide–Sepharose column
 .4 ml prepared as described by Mumby and Gilman
w x16 and equilibrated with 100 mM NaCl, 20 mM
 .TrisrHCl, pH 7.5 buffer A . After extensive wash-
ing with buffer A, the antibodies were eluted from
the column with 0.2 M glycine, pH 2.2. The fractions
were collected as described for the protein A column.
Neutralized fractions that contained proteins, as de-
termined by absorbance at 280 nm, were pooled,
dialyzed overnight against buffer A and adjusted to
the desired concentration by ultrafiltration.
2.2. OK cell membranes preparation and treatments
Wild type OK cells, a gift from W. Pfaller Uni-
.versity of Innsbruck, Austria , were initially cultured
 .in DMEMrF12 Gibco buffered with 15 mM
Hepesr14 mM bicarbonate, containing 50 Urml
penicillin, 50 mgrml streptomycin and 10% fetal
 .bovine serum FBS . Cells were used between pas-
sages 110 and 130. Cells were plated in 150 mm
 .tissue culture dishes Corning and incubated in a
humidified atmosphere of 95% air, 5% CO at 378C.2
They were studied after 6–8 days at which time they
were confluent. Membranes were prepared from cells
that had been washed once with ice-cold 150 mM
NaClr5 mM Tris–HCl, pH 7.2 and once with 5 mM
Hepes–KOH, pH 7.2. Cells were scraped from dishes
into the latter solution and homogenized by passing
six times through a number 18 needle. Nuclei and
cell debris were removed by centrifugation for 5 min
at 279=g. The supernatant was then centrifuged for
30 min at 48 000=g and the pellets resuspended in
w x5 mM Hepes–KOH, 0.5 mM EDTA, pH 7.2 17 .
The effects of high and low phosphate on OK cells
were examined by incubating cells with 0 or 1 mM
phosphate. In one experiment, cells were incubated
for 6 h without FBS in DMEM containing 0.1%
bovine serum albumin and either 0 or 1 mM phos-
phate before measuring uptake and isolating mem-
branes. In another experiment, they were incubated
for the first four days with DMEMrF12, 10% FBS
followed by three days in DMEM 10% FBS. These
cells were then incubated for 19 h in DMEM 0.1%
BSA with either 0 or 1 mM phosphate. The effect of
parathyroid hormone was examined in cells fed
DMEMrF12 10% FBS for seven days followed by
18 h with 0.1% BSA replacing the FBS. These cells
were then exposed for 2 h to 10y8 M PTH or its
vehicle.
2.3. Phosphate uptake measurements
For measurement of 32P uptake, cells were washed
two times with a buffer containing 137 mM NaCl,
5.4 mM KCl, 1.2 mM MgSO , 2.8 mM CaCl , 10 mM4 2
HepesrTris, pH 7.4. The buffer was prewarmed to
378C. Na-dependent uptake was measured at 378C for
32  .5 min by adding 0.1 mM K H PO 1 mCirml to2 4
the buffer. Uptake was terminated by aspirating the
buffer and washing the cells four times with 1 ml of
ice-cold buffered saline 145 mM NaCl, 10 mM
.TrisrHCl, pH 7.4 . An aliquot of cells solubilized in
0.5 M NaOH was used for scintillation counting after
being neutralized with 1 M CH COOH. Another3
aliquot was used for protein determination by the
Lowry method. Each day measurements were carried
out in duplicate or triplicate plates of cells and the
results are given for the mean of at least three such
experiments.
2.4. Preparation of crude membranes
Brain from human, rat, rabbit, hamster and several
tissues from mouse intestine, liver, spleen, kidney,
testis, pancreas, heart, thymus, lungs, muscle and
.brain were isolated and homogenized with a Poly-
 .tron homogenizer Brinkman, Switzerland . Intact
cells were removed by centrifugation at 1000=g for
10 min. The supernatant was then centrifuged at
33 000=g for 30 min to yield a pellet enriched in
crude membranes. This pellet was resuspendend in
buffer composed of 50 mM mannitol, 20 mM
HepesrTris pH 7.5, and the samples were kept at
y808C until they were used.
2.5. Western blot analysis
Sodium dodecyl sulfate polyacrylamide gel elec-
 .trophoresis SDS–PAGE was performed with a
Mini-Protean II electrophoresis apparatus Bio-Rad,
.Mississauga, Ont. and the Laemmli buffer system
w x  .18 . The separating gel contained 7.5% wrv acryl-
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amide. Unless indicated otherwise, prior to elec-
trophoresis, the protein samples were mixed with
Laemmli’s sample buffer without boiling. Elec-
trophoresis was carried out at a constant current of
10 mAr0.75 mm gel. Molecular mass determinations
were based on a calibration curve prepared with
 .standard proteins Bio-Rad . Following electrophore-
sis, the proteins were transferred electrophoretically
 .onto polyvinylidene difluoride PVDF membranes
 .Millipore, Mississauga, Ont. with a Milliblot
Graphite Electroblotter I apparatus Millipore, Mis-
. 2sissauga, Ont. at a constant current of 1 mArcm for
1 h at room temperature. Hydrophobic or non-specific
binding sites of PVDF membranes were blocked
 .overnight in 150 mM NaCl, 0.2% wrv Tween 20
 .and 50 mM TrisrHCl, pH 7.5 buffer B , at 48C. The
membranes were brought to room temperature and
incubated for 1 h with the anti-peptide antibody di-
luted 1r10 000 in buffer B. The membranes were
then washed three times by gentle agitation in buffer
B for 10 min, incubated for 1 h with an anti-rabbit
IgG linked to horseradish peroxidase and diluted
 .1r10 000 Amersham, Oakville, Ont. in buffer B.
After a final wash, labelled antigens were revealed
 .with enhanced chemiluminescence ECL detection
 .system Amersham, Oakville, Ont. . Fuji films which
were preflashed with a Sensitize flashgun unit
 .Amersham, Oakville, Ont. were exposed to the
membranes, developed and analyzed using a densito-
 .meter Molecular Dynamics .
2.6. Deglycosylation
OK cell membrane proteins were solubilized in
0.5% SDS for 10 min at room temperature and di-
 .luted 5-fold with 1% wrv n-octyl b-D-gluco-
 .pyranoside, 1% vrv b-mercaptoethanol, 20 mM
TrisrHCl, pH 8. Endoglycosidase FrN-glycosidase
 .F mixture Boehringer-Mannheim, Laval, Que. was
added at 2 Urmg protein and the reaction was al-
lowed to proceed for 16 h at 258C. Laemmli’s sample
buffer was then added and samples underwent the
Western blot procedures.
2.7. Protein isolation by electroelution on a SDS–
PAGE mini prep cell column
 .Membrane proteins 500 mg isolated from mouse
brain were resolved on a 7.5% acrylamide SDS–
 .PAGE Mini Prep Cell column Bio-Rad with a
running gel height of 5 cm and a stacking gel of 1 cm
 .4% acrylamide . The electrophoresis was carried out
at a constant current of 4 mA. Fractions of 180 ml
were collected at a flow rate of 60 mlrmin and
assayed by Western blot for immunodetection of p85
and the 70–72 kDa protein. Fractions containing these
proteins were identified and pooled for further analy-
sis.
2.8. Limited chymotryptic digestion
Membrane protein samples were solubilized with
 .1% wrv SDS for 20 min at room temperature and
then centrifuged at 50 000=g for 15 min. Super-
natant containing solubilized proteins was then incu-
bated with chymotrypsin for 30 min at 378C in a
buffer composed of mannitol 300 mM, HepesrTris
20 mM, pH 7.5. The reaction was stopped by dilution
of the reaction media with the same buffer containing
PEFABLOC at 1 mgrml. Samples underwent elec-
Fig. 1. Hypothetical topographic representation of Glvr-1 in the
membrane based on the secondary structure of Glvr-1 proposed
w xby Johann et al. 19 and on the analysis of the primary sequence
using the MacVector software Kodak Laboratory and Research
.Products . This representation is shown looking into the plane of
the bilayer. According to this model, Glvr-1 could possess up to
ten transmembrane domains with both N- and C-terminal seg-
ments facing the cytoplasmic side of the membrane. Numbers at
each end of transmembrane segments represent residues. The
peptide region against which the antibodies have been raised is
 .located within the large hydrophilic loop residues 251–512 .
 .Potential N-glycosylation sites are indicated by an asterisk ) .
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 .trophoresis 15% acrylamide gels and Western blot
analysis was carried out as described previously.
3. Results
The predicted Kyte and Doolittle hydropathy pro-
file suggests that Glvr-1 possesses ten transmembrane
 .domains Fig. 1 . According to this model, both
amino and carboxy ends would be within the cyto-
plasmic surface of the membrane. The region against
which the antibodies are directed is located in the
large intracytoplasmic loop of Glvr-1 residues 251–
.512 .
Polyclonal antibodies directed against a 14-amino
acid portion of the cloned sodiumrphosphate co-
transporter Glvr-1 were raised in rabbits, affinity-
purified and used to determine the presence of related
proteins in brain crude membranes from human, rat,
rabbit, hamster, mouse, and in plasma membranes
from OK cells and umbilical cord endothelial cells
  ..Fig. 2 A . The last seven C-terminal amino acids of
this peptide also corresponds to a portion of the rat
Ram-1 transporter. Analysis revealed a protein of
 .about 85 kDa designated p85 in brain of rat, rabbit,
hamster, mouse and in OK cells. No proteins were
detected in crude membranes from human brain or in
umbilical cord endothelial cells. In mouse brain, an-
other strong band was also detected, which corre-
sponds to a protein of about 70–72 kDa. This mouse
protein was peptide displaceable, showing the speci-
 .ficity of the antibodies for this protein not shown .
p85 was also detected in several mouse tissues such
as kidney, heart, thymus, muscle and brain, although
in liver and testis, there was slight variations in
electrophoretic mobility of the protein. However, p85
was not detected in intestine, spleen, pancreas or
lungs, possibly because of its absence or its weak
  ..expression in those tissues Fig. 2 B . In a previous
study, Glvr-1 and Ram-1 mRNA was detected in all
rat tissues except in spleen, although intestine, testis
w xand pancreas were not assayed 10 . In another report,
Glvr-1 mRNA was detected in all mouse tissues
except for stomach intestine, testis and pancreas
. w xwere not tested 19 .
 .Fig. 2. Immunodetection of proteins in crude membrane preparations from OK cells and umbilical cord endothelial cells Endo and from
 .  .human, rat, rabbit, hamster and mouse brain A and mouse tissues B using polyclonal antibodies directed against type III
 .sodiumrphosphate cotransporter Glvr-1rRam-1. Protein samples 12 mg were resolved by SDS–PAGE using 7.5% polyacrylamide gels.
Immunodetection was performed as described under Section 2 and antibody binding was detected using donkey horseradish peroxidase-
linked anti-rabbit IgG antibodies. Labelled antigens were revealed by ECL detection system. Comparable data were obtained in three
independent experiments performed in duplicate.
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Fig. 3. Antibody specificity and displacement studies. Western blot analysis of OK cell membrane proteins was performed as described
under Section 2 with addition of antigenic peptide during the incubation with the primary antibody. The control sample i.e. without any
. y10 y3peptide is represented by ‘‘Ctl’’ and the peptide concentrations utilized ranged from 10 to 10 M.
The specificity of the antibody was examined by
comparing the detection profiles obtained after incu-
bation of the PVDF membranes with affinity-purified
antibodies in the presence of increasing concentra-
 .tions of antigenic peptide Fig. 3 . The detection of
p85 from OK cell membranes was reduced approxi-
mately 84% that of the control by the addition of
10y10 M peptide for a 1r10 000 dilution of the anti-
body preparation and 10y6 M peptide was sufficient
to prevent any binding of the antibodies to p85.
Since previous reports have demonstrated a critical
role of sulfhydryl groups on the function and struc-
w xture of sodium-phosphate uptake 20–23 , the influ-
 .ence of b-mercaptoethanol b-EtSH and heating on
the immunodetection of p85 was investigated in OK
 .cells Fig. 4 . Denaturation by heating of the samples
prior to electrophoresis had no apparent influence on
the detection of p85. When electrophoresis was car-
ried out in the presence of b-EtSH, the immunodetec-
tion of the 85 kDa protein was enhanced compared to
Western blots where b-EtSH was excluded from
samples. However, under all conditions only one
major band corresponding to p85 was observed. To
further characterize this protein, the addition of b-
 .EtSH to protein samples without boiling before
electrophoresis was used in the following experi-
ments.
Type II phosphate transporters are up- and down-
regulated by a low-phosphate diet and by PTH, re-
w xspectively 13,24 . To study the effects of those strong
phosphate uptake modulators on p85, OK cells were
cultured in absence of phosphate or in presence of
PTH. Following culture in absence of phosphate,
phosphate uptake was 2–3 times higher than the
uptake of cells cultured in presence of 1 mM phos-
 .phate Table 1 . Also, uptake in PTH-treated cells
showed a 75% decrease compared to control cells
 .Table 2 . However, these treatments did not alter the
 .net level of p85 present in the membrane Fig. 5 .
This clearly shows that p85 expression is not affected
by extracellular phosphate levels in OK cells or in
response to treatment with PTH.
Fig. 4. Immunodetection of p85 from OK cell membranes under
various conditions. Prior to electrophoresis, protein samples were
 .  .  .  .either boiled q or not y in the presence q or absence y
 .of b-EtSH. Proteins 12 mgrwell were resolved by SDS–PAGE
using 7.5% polyacrylamide gels and p85 was immunodetected as
described under Section 2.
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Table 1
Effect of phosphate treatments on phosphate uptake in OK cells
Treatment Phosphate uptake Phosphate uptake
in cells cultured in cells cultured
without any in presence of
phosphate 1 nM phosphate
 nmolrmg nmolrmg
. .proteinr5 min proteinr5 min
Treatment A 17.94 9.68
17.80 8.72
16.75 8.10
Treatment B 12.43 3.85
12.66 4.05
12.29 4.99
In treatment A, cells were incubated for 6 h without FBS in
DMEM containing 0.1% bovine serum albumin and either 0 or
1 mM phosphate before measuring uptake and isolating mem-
branes as described under Section 2. In treatment B, they were
incubated for the first four days with DMEMrF12, 10% FBS
followed by three days in DMEM 10% FBS. These cells were
then incubated for 19 h in DMEM 0.1% BSA with either 0 or
1 mM phosphate. The results are given for three experiments for
each treatment.
Since the amino acid sequence of Glvr-1 possesses
four potential N-glycosylation sites, glycosidase
treatments were performed on OK cell membrane
proteins to investigate the glycosylation state of p85
 .Fig. 6 . Protein samples were treated for 16 h with a
mixture of endoglycosidase FrN-glycosidase F,
which hydrolyzes N-glycans of the ‘‘high mannose’’
w xand the ‘‘complex’’ type 25 , and then processed for
Western blotting. The Glvr-1rRam-related protein
p85 showed no alteration in its electrophoretic mobil-
ity following glycosidase treatment.
Table 2
Effect of PTH treatment on phosphate uptake in OK cells
Phosphate uptake in cells Phosphate uptake in cells
cultured without any PTH cultured in presence of
y810 M PTH
 .  .nmolrmg proteinr5min nmolrmg proteinr5min
13.5 3.60
13.8 3.20
The effect of parathyroid hormone was examined in cells fed
DMEMrF12 10% FBS for 7 days followed by 18 h with 0.1%
BSA replacing the FBS. These cells were then exposed for 2 h to
10y8 M PTH or its vehicle before measuring uptake and isolating
membranes as described under Section 2. The results are given
for two experiments.
Fig. 5. Effect of phosphate and PTH on the immunodetection of
p85. Membranes were isolated from OK cells grown under
 .  .control conditions Ctl , in absence of inorganic phosphate yP ,i
 .or in presence of PTH qPTH in culture medium, as described
in Section 2. Protein samples were analyzed by Western blot as
described under Section 2.
We investigated the relationship between the two
proteins detected in mouse brain, i.e. p85 and the
70–72 kDa protein. First, both proteins were isolated
using an SDS–PAGE column to study them sepa-
 .rately Fig. 7 . Western blots were done with every
second fraction collected to determine in which frac-
tions we could find proteins around 70–72 and
85 kDa. Fractions containing each of these proteins
were pooled separately, i.e. fractions 22–24 for the
70–72 kDa protein and fractions 44–48 for p85. Af-
Fig. 6. Effect of endoglycosidase FrN-glycosidase F treatment
on the electrophoretic mobility of p85 from OK cells. Protein
samples were first solubilized in 0.5% SDS and then diluted
 .  .5-fold with 1% wrv n-octyl b-D-glucopyranoside, 1% vrv
b-mercaptoethanol, 20mM TrisrHCl, pH 8. The samples were
 .  .incubated at 258C for 16 h with qEndo or without Ctl 2 Urmg
of the enzymatic mixture. Protein samples were analyzed by
Western blot as described under Section 2.
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 .Fig. 7. Isolation of mouse brain proteins using an SDS–PAGE column. Membrane proteins 500 mg isolated from mouse brain were
 .resolved on a SDS–PAGE column Bio-Rad as described in Section 2. Fractions of 180 ml were collected at a rate of 60 mlrmin and
assayed for immunodetection of p85 and proteins of 70–72 kDa. Fractions containing these proteins were identified and pooled for further
analysis.
ter limited chymotrypsin proteolysis, two fragments
  ..were obtained from p85 Fig. 8 A which were
identical to those found in the 70–72 kDa protein
  ..fragment pattern Fig. 8 B . These fragments are
identified as F26 and F17. This finding demonstrates
that p85 and the 70–72 kDa protein from mouse brain
are very similar in their amino acid sequence and
possess common chymotrypsin digestion sites.
Third, to investigate the relationship between p85
from OK cells with p85 from mouse brain, we also
Fig. 8. Chymotrypsin proteolysis of isolated fractions containing p85 and 70–72 kDa-protein from mouse brain. Isolated protein fractions
 .  .  .  .containing either p85 A or 70–72 kDa B were incubated with 0 and 1 A or 0.01 U B chymotrypsin for 30 min at 378C and were
 .  .used for electrophoresis on 15% acrylamide gels and Western blot analysis as described under Section 2. As controls Ctl , protein
samples were simply loaded on the gel for electrophoresis without any treatment.
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Fig. 9. Chymotrypsin proteolysis of OK cell membrane proteins.
 .Membrane protein samples were solubilized with 1% wrv SDS
for 20 min at room temperature and then centrifuged at 50 000= g
for 15 min. Supernatant containing solubilized proteins was then
incubated with 0 and 1 U chymotrypsin, as described under
Section 2. Samples underwent electrophoresis on 15% acrylamide
gels and Western blot analysis as described under Section 2. As a
 .control Ctl , protein sample was simply loaded on the gel for
electrophoresis without any treatment.
performed limited chymotrypsin proteolysis on OK
 .cell membranes Fig. 9 . After enzymatic cleavage,
both F26 and F17 fragments were also detected in
membranes from OK cells, demonstrating that p85
detected in these two species possesses a similar
amino acid sequence. In the control, the many bands
detected below 45 kDa are due to non-specific bind-
ing of the antibodies since they were not displaced by
 .the antigenic peptide not shown .
4. Discussion
To study the human receptor for the gibbon ape
leukemia virus Glvr-1, polyclonal antibodies were
raised in rabbits against a synthetic peptide corre-
sponding to a 14-amino acid segment of the cloned
w xreceptor’s deduced sequence 9 . The Gly-408 to
Tyr-421 segment was chosen because hydropathy
w xanalysis 26 of the amino acid sequence of Glvr-1
suggests that it is fairly hydrophilic and because its
antigenic index seemed adequate. This segment had
to be very carefully selected since Glvr-1 has a
relatively hydrophobic amino acid composition. The
epitope we used to raise these antibodies is present in
homologs to human receptor Glvr-1, two different
w xmurine homologs 12,19 and a Chinese hamster ho-
w xmolog 27 . The last seven C-terminal amino acids of
this epitope are also present in murine Ram-1, thus
cross-reactivity of the antibodies with this other
member of the type III phosphate transporter gene
family is possible. The affinity-purified antibodies
were used in Western blot experiments to identify
immunoreactive proteins in OK cell membranes as
well as in brain membranes from various species.
Using this technique, a single band representing a
 .protein of about 85 kDa p85 was immunodetected
in rat, rabbit, hamster, mouse and OK cells. In mouse
brain, a second protein of about 70–72 kDa was also
detected. These apparent molecular masses are some-
what in good agreement with that calculated from the
amino acid sequences of Glvr-1 or Ram-1 which are
74 and 70 kDa, respectively, without any post-transla-
w xtional modifications 9 . However, distinction be-
tween Glvr-1 and Ram-1 cannot be done since a
 .portion seven amino acids of the epitope chosen to
raise our antibodies is identical in both transporters.
Although detection of Glvr-1 and Ram-1 mRNAs in
several rat tissues were performed by Northern blot
w xanalysis 10 , this is the first report showing the
Western blot detection of Glvr-1rRam-1 by poly-
clonal antibodies. The cross-reactivity of our antibod-
ies with proteins from rat, rabbit, hamster, mouse and
OK cell indicates that this receptor, which is a
sodiumrphosphate cotransporter, is a well conserved
protein since all these species possess a similar epi-
tope. The detection of Glvr-1rRam-1 in several
mouse tissues is in agreement with a constitutive
 .‘‘housekeeping’’ role of type III phosphate trans-
porters in most cells to absorb the readily available
phosphate from interstitial fluid for normal cellular
functions. A previous study has also shown the pres-
ence of Glvr-1 and Ram-1 mRNA in many rat tissues
w x10 . The role of type III phosphate transporters
greatly differs from those of the adaptive type II
w xsystem which is strictly localized in the kidney 28 .
The absence of p85 in human brain can be explained
by degradation of the sample since many hours
elapsed between removal of the sample from the
patient and the resulting membrane preparation.
b-EtSH reacts with the existing disulfide bonds in
a protein to reduce them. In this study, the presence
of b-EtSH increased the amount of the immunode-
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tected p85, but there was no change in its apparent
molecular mass. This suggests that b-EtSH enhances
the accessibility of the epitope to the antibodies by
reducing disulfide bonds.
Dietary phosphate restriction produces an adaptive
increase in sodiumrphosphate cotransport by OK
w xcells 29 which is characterized by an increase in the
mRNA and protein levels of NaP -4, a type IIi
w xsodiumrphosphate cotransporter 30 . Accordingly,
exposure of rat fibroblasts to phosphate-free medium
has been shown to cause a 3-fold increase in phos-
phate transport, which is accompanied by a 3- to
5-fold increase in Glvr-1 and Ram-1 mRNA levels
 . w xNorthern blot experiments 10 . In our study, West-
ern blots experiments showed that the expression of
p85 was not affected by phosphate deprivation. These
contrasting results could be explained by different
modes of regulation in the species studied i.e. rat
.fibroblasts vs. OK cells , by the conditions under
which the experiments were carried out duration of
.the diet , or by the delay of mRNA to be translated
into detectable membrane proteins. It has already
been established that OK cells possess at least one
other type of sodiumrphosphate cotransporter type
.II , NaP -4, which is up-regulated by phosphate depri-i
w xvation 31 . However, such a discrepancy between
overexpression of mRNA in rat fibroblasts and steady
amount of p85 in OK cell membranes following
phosphate deprivation remains to be elucidated.
Since regulation of phosphate transporter function
may occur through PTH activation of kinase, and
since multiple consensus phosphorylation sites are
present in Glvr-1, particularly in the large cytoplas-
w xmic loop 32 , we examined the effect of PTH on p85
in OK cells. PTH did not alter the expression of p85
in OK cells, contrarily to NaPi-II-type transporters
which are tightly regulated following PTH treatments
w x24 .
According to its amino acid sequence, Glvr-1 pos-
sesses four potential sites of N-glycosylation: Asn-96,
w xAsn-371, Asn-415 and Asn-497 9 . Since the appar-
ent molecular mass obtained for Glvr-1rRam-1-re-
lated protein was 85 kDa, and the predicted molecular
mass from the cDNA is 74 kDa for Glvr-1 and 70 kDa
w xfor Ram-1 9 , the glycosylation state of p85 was
investigated. According to our results, the discrepan-
cies between both observed and predicted molecular
masses cannot be explained by N-glycosylation since
no variation of the immunodetection of p85 was
observed following glycosidase treatment. This result
is not surprising since the hypothetical topographic
representation of Glvr-1 in its lipid bilayer shows all
three potential N-glycosylation sites facing the cyto-
w xplasm 11,19 . Possibly, Glvr-1rRam-1 possesses
other post-translational modifications that could alter
its electrophoretic mobility, or is also present as a
larger precursor.
The two identical fragments obtained for p85 from
mouse and OK cells and for the 70–72 kDa protein
from mouse after chymotryptic cleavage demonstrate
the very close structural relationship between these
proteins. These fingerprinting experiments show that
p85 from both species possesses a common portion
of their amino acid chains that contains the same
chymotryptic cleavage sites. Also, these findings sug-
gest that the mouse 70–72 kDa protein could be a
peptide fragment from p85, or a type III transporter
 .Glvr-1 or Ram-1 without any post-translational
modification since its mass is closer to the predicted
mass of these transporters.
In conclusion, these data demonstrate for the first
time a Western blot detection of a type III phosphate
transporter using polyclonal antibodies. This report
provides evidence that, conversely to type I and
adaptive type II phosphate transporters which are
localized in the kidney, this third type of transporter
is ubiquitous and probably absorbs the readily avail-
able phosphate from interstitial fluid for normal cellu-
lar functions in many species, serving as a
‘‘housekeeping’’ transporter. This is also the first
report showing that p85 is not regulated by low
extracellular phosphate nor by PTH, contrarily to
type II phosphate transporters.
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